Published in J Natl Cancer Inst on September 07, 2005
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer (2007) 3.77
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol (2009) 2.94
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst (2009) 2.85
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol (2012) 2.62
Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol (2011) 2.53
Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst (2009) 2.50
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol (2007) 2.30
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol (2009) 2.01
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
AN OVERVIEW OF ELASTOGRAPHY - AN EMERGING BRANCH OF MEDICAL IMAGING. Curr Med Imaging Rev (2011) 1.73
Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology (2007) 1.67
The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients. J Urol (2010) 1.50
Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. Eur Urol (2015) 1.44
Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer (2012) 1.38
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer (2008) 1.37
Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology (2008) 1.27
Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res (2009) 1.27
Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.26
Prostate cancer screening: current status and future perspectives. Nat Rev Urol (2010) 1.23
Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology (2007) 1.22
Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control (2009) 1.15
Active surveillance for prostate cancer: trials and tribulations. World J Urol (2008) 1.15
Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther (2010) 1.14
What is low-risk prostate cancer and what is its natural history? World J Urol (2008) 1.09
Gleason grade progression is uncommon. Cancer Res (2013) 1.09
Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst (2005) 1.02
Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol (2013) 1.00
Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol (2010) 0.96
Prognostic determinants in prostate cancer. Cancer J (2011) 0.95
Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? Am J Pathol (2010) 0.95
Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum Genet (2007) 0.94
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. BJU Int (2011) 0.92
Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr (2012) 0.90
The face of high risk prostate cancer. World J Urol (2008) 0.87
Prostate cancer: a review of active surveillance. Res Rep Urol (2014) 0.86
Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev (2009) 0.86
Substratification of high-risk localised prostate cancer treated by radical prostatectomy. World J Urol (2008) 0.84
A new approach to understanding racial disparities in prostate cancer treatment. J Geriatr Oncol (2013) 0.84
Management of low (favourable)-risk prostate cancer. BJU Int (2011) 0.84
Active surveillance and focal therapy for low-intermediate risk prostate cancer. Transl Androl Urol (2015) 0.82
Successful external validation of a model to predict other cause mortality in localized prostate cancer. BMC Med (2016) 0.81
Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res (2016) 0.81
Temporal changes in the clinical approach to diagnosing prostate cancer. J Natl Cancer Inst Monogr (2012) 0.80
Prostate cancer: Relationship between vascular diameter, shape and density and Gleason score in needle biopsy specimens. Adv Biomed Res (2013) 0.77
Oncologic outcomes following radical prostatectomy in the active surveillance era. Can Urol Assoc J (2013) 0.77
Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer. Oncol Lett (2015) 0.77
Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy. World J Urol (2008) 0.76
Does true Gleason pattern 3 merit its cancer descriptor? Nat Rev Urol (2016) 0.76
Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. Prostate Cancer Prostatic Dis (2015) 0.75
Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia. Can Urol Assoc J (2015) 0.75
Management of low-risk prostate cancer. World J Urol (2008) 0.75
What is the risk posed by prostate cancer? J Natl Cancer Inst Monogr (2012) 0.75
Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer. Prostate Cancer (2015) 0.75
Should all men having a radical prostatectomy have a pelvic lymph node dissection? No. Can Urol Assoc J (2010) 0.75
Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma. Med Sci Monit (2017) 0.75
Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investig Clin Urol (2016) 0.75
More judicious use of expectant management for localized prostate cancer over the past two decades. J Urol (2016) 0.75
The role of metadata and strategies to detect and control temporal data bias in environmental monitoring of soil contamination. Environ Monit Assess (2011) 0.75
Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. J Surg Oncol (2016) 0.75
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Statistical practice in high-throughput screening data analysis. Nat Biotechnol (2006) 5.85
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Sun exposure and mortality from melanoma. J Natl Cancer Inst (2005) 5.08
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
Physician scores on a national clinical skills examination as predictors of complaints to medical regulatory authorities. JAMA (2007) 3.27
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ (2010) 3.09
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Identification in administrative databases of women dying of breast cancer. J Clin Oncol (2006) 2.47
Do OSCAR winners live longer than less successful peers? A reanalysis of the evidence. Ann Intern Med (2006) 2.46
Association between licensure examination scores and practice in primary care. JAMA (2002) 2.44
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care (2011) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Random measurement error and regression dilution bias. BMJ (2010) 2.20
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol (2005) 1.97
Association between age and graft failure rates in young kidney transplant recipients. Transplantation (2011) 1.85
National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol (2012) 1.84
The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol (2005) 1.79
Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med (2012) 1.78
Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol (2012) 1.77
Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med (2011) 1.76
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol (2007) 1.74
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol (2011) 1.72
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol (2004) 1.68
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.66
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology (2013) 1.66
Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol (2010) 1.64
Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol (2010) 1.60
Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer (2004) 1.60
Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int (2008) 1.59
Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol (2007) 1.57
Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int (2010) 1.57
Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology (2012) 1.56
Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. J Urol (2002) 1.54
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol (2013) 1.53
Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology (2012) 1.53
The structural equation modeling technique did not show a response shift, contrary to the results of the then test and the individualized approaches. J Clin Epidemiol (2005) 1.46
Racial variation in the quality of surgical care for bladder cancer. Cancer (2013) 1.45
Discordance between cross-sectional and longitudinal studies for the effect of dust on COPD: why? COPD (2005) 1.43
ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. Eur Urol (2012) 1.42
Combining longitudinal studies of PSA. Biostatistics (2004) 1.40
Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology (2008) 1.39
Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care (2007) 1.38
Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care (2003) 1.37
13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol (2007) 1.36
Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol (2008) 1.33
The effect of a task-oriented walking intervention on improving balance self-efficacy poststroke: a randomized, controlled trial. J Am Geriatr Soc (2005) 1.28
Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol (2010) 1.26
Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care (2010) 1.24
Blood pressure and adiposity in children and adolescents. Circulation (2004) 1.24
Internet health resources and the cancer patient. Cancer Invest (2008) 1.23
C-reactive protein and features of the metabolic syndrome in a population-based sample of children and adolescents. Clin Chem (2004) 1.21
Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res (2005) 1.18
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med (2005) 1.16
The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. J Urol (2011) 1.16
Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol (2006) 1.16
Evaluating the validity of multiple imputation for missing physiological data in the national trauma data bank. J Emerg Trauma Shock (2009) 1.15
On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. J Urol (2007) 1.14
Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.14
Prostate cancer on the Internet--information or misinformation? J Urol (2006) 1.14
Discordant secular trends in elevated blood pressure and obesity in children and adolescents in a rapidly developing country. Circulation (2009) 1.13
Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol (2010) 1.12
Quality of life issues in bladder cancer patients following cystectomy and urinary diversion. Urol Clin North Am (2005) 1.12
Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. J Urol (2011) 1.11
A multiple imputation model for imputing missing physiologic data in the national trauma data bank. J Am Coll Surg (2009) 1.11
Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. BJU Int (2011) 1.10
Balance self-efficacy and its relevance to physical function and perceived health status after stroke. Arch Phys Med Rehabil (2006) 1.10
Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol (2011) 1.10
Comparison of three methods for estimating the standard error of the area under the curve in ROC analysis of quantitative data. Acad Radiol (2002) 1.09
An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol (2004) 1.09
Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat. Health Aff (Millwood) (2012) 1.09
Secular trends of antibacterial prescribing in UK paediatric primary care. J Antimicrob Chemother (2010) 1.08